{"protocolSection":{"identificationModule":{"nctId":"NCT03936335","orgStudyIdInfo":{"id":"R668-AD-1760"},"secondaryIdInfos":[{"id":"43838","type":"REGISTRY","domain":"EU HMA-EMA Catalogue"}],"organization":{"fullName":"Regeneron Pharmaceuticals","class":"INDUSTRY"},"briefTitle":"An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)","officialTitle":"Dupilumab and Pregnancy Outcomes: A Retrospective Cohort Study Using Administrative Healthcare Databases (Dupi PODS)"},"statusModule":{"statusVerifiedDate":"2025-07","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2019-09-30","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2027-01-21","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-01-21","type":"ESTIMATED"},"studyFirstSubmitDate":"2019-04-30","studyFirstSubmitQcDate":"2019-04-30","studyFirstPostDateStruct":{"date":"2019-05-03","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-07-30","lastUpdatePostDateStruct":{"date":"2025-08-03","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Regeneron Pharmaceuticals","class":"INDUSTRY"},"collaborators":[{"name":"Sanofi","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The objective of this study is to describe and compare the incidence of adverse pregnancy outcomes (spontaneous abortion/miscarriage, stillbirth) and prevalence of adverse infant outcomes (major congenital malformations \\[MCMs\\], small for gestational age \\[SGA\\]) in women with AD who are treated with dupilumab during pregnancy relative to women with AD who are not treated with dupilumab during pregnancy."},"conditionsModule":{"conditions":["Adverse Pregnancy Outcomes","Atopic Dermatitis"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"COHORT","timePerspective":"RETROSPECTIVE"},"enrollmentInfo":{"count":3930,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Dupilumab cohort","description":"Exposed to dupilumab during the relevant exposure window:\n\n* First trimester\n* Pregnancy","interventionNames":["Drug: dupilumab"]},{"label":"Other systemic therapy or phototherapy cohort","description":"Exposed to systemic medications other than dupilumab or to phototherapy during the relevant exposure window:\n\n* First trimester\n* Pregnancy"},{"label":"Unexposed cohort","description":"* Not exposed to systemic medications (including dupilumab) or phototherapy; and\n* Received topical prescription therapy, or a second diagnosis for AD on a date that differs from the base population qualifying AD diagnosis date during the relevant exposure window:\n* First trimester\n* Pregnancy"}],"interventions":[{"type":"DRUG","name":"dupilumab","description":"No study drug will be administered. This study is based on an analysis of automated medical and prescription claims, supplemented by information abstracted from the medical record.","armGroupLabels":["Dupilumab cohort"],"otherNames":["REGN668","DupixentÂ®","SAR23189"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Prevalence of MCMs","description":"Initially identified through the presence of corresponding codes on the insurance claims, confirmed through medical record review for infant outcomes: 01 April 2017 through December 2024","timeFrame":"Up to 21 months"}],"secondaryOutcomes":[{"measure":"Incidence of spontaneous abortion or miscarriage","description":"Identified through the presence of corresponding codes on the insurance claims for pregnancy outcomes: 01April 2017 through 31 March 2024","timeFrame":"Up to 9 months"},{"measure":"Incidence of stillbirth","description":"Identified through the presence of corresponding codes on the insurance claims for pregnancy outcomes: 01April 2017 through 31 March 2024","timeFrame":"Up to 9 months"},{"measure":"Incidence of SGA","description":"Identified through the presence of corresponding codes on the insurance claims for infant outcomes: 01 April 2017 through December 2024","timeFrame":"Up to 21 months"}]},"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Continuous medical and pharmacy benefit coverage for at minimum 6 months prior to and including the estimated LMP\n* Diagnosis code indicative of AD in the period from up to 1 year prior to the estimated LMP through the end of the pregnancy\n\nNote: Other Protocol Defined Inclusion / Exclusion Criteria Apply","healthyVolunteers":false,"sex":"FEMALE","genderBased":true,"minimumAge":"18 Years","maximumAge":"49 Years","stdAges":["ADULT"],"studyPopulation":"Adult women with AD who are pregnant between 01 April 2017 and 31 March 2024 (with the start of pregnancy to be defined by the estimated last menstrual period (LMP))","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"centralContacts":[{"name":"Clinical Trials Administrator","role":"CONTACT","phone":"844-734-6643","email":"clinicaltrials@regeneron.com"}],"overallOfficials":[{"name":"Clinical Trial Management","affiliation":"Regeneron Pharmaceuticals","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Regeneron Research Site","status":"RECRUITING","city":"Boston","state":"Massachusetts","zip":"02215","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D003876","term":"Dermatitis, Atopic"}],"ancestors":[{"id":"D012873","term":"Skin Diseases, Genetic"},{"id":"D030342","term":"Genetic Diseases, Inborn"},{"id":"D009358","term":"Congenital, Hereditary, and Neonatal Diseases and Abnormalities"},{"id":"D003872","term":"Dermatitis"},{"id":"D012871","term":"Skin Diseases"},{"id":"D017437","term":"Skin and Connective Tissue Diseases"},{"id":"D017443","term":"Skin Diseases, Eczematous"},{"id":"D006969","term":"Hypersensitivity, Immediate"},{"id":"D006967","term":"Hypersensitivity"},{"id":"D007154","term":"Immune System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C582203","term":"dupilumab"}]}},"hasResults":false}